Form 4: Omnicell Director Bruce E. Scott Receives Equity Grant as Board Compensation

Omnicell, Inc. Director Bruce E. Scott was granted 6,862 restricted shares of common stock as compensation for his board services, increasing his total beneficial ownership to 22,973 shares.

Summary

• Bruce E. Scott, a Director of Omnicell, Inc. (OMCL), was granted 6,862 shares of common stock on June 1, 2025.
• The shares were granted as restricted stock under the Issuer's equity incentive plan, specifically for services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan.
• The grant price for these shares was $0, indicating they were awarded as compensation rather than purchased.
• Following this transaction, Mr. Scott's beneficial ownership of Omnicell common stock increased to 22,973 shares.
• The granted shares are scheduled to vest in full on the one-year anniversary of the grant date, which would be June 1, 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. This is a routine and expected transaction (director compensation via equity), which aligns the director's interests with shareholders. It does not indicate any immediate operational or financial issues, nor does it suggest extraordinary positive developments beyond standard corporate governance.

Positives

• The grant of restricted shares to Director Bruce E. Scott aligns his interests with those of the shareholders, as his compensation is tied to the company's long-term performance.
• This transaction is part of a pre-existing Board of Directors Compensation Plan, indicating a structured and transparent approach to executive and board remuneration.

Future Outlook

The granted restricted shares are scheduled to vest in full on the one-year anniversary of the grant date, which will be June 1, 2026, at which point they will become fully owned by Mr. Scott.

Management Comments

• The grant of restricted shares was made 'pursuant to the Issuer's Board of Directors Compensation Plan,' indicating adherence to established corporate compensation policies.

Industry Context

The practice of compensating directors with equity, such as restricted stock, is a common and widely accepted practice across various industries for publicly traded companies. It serves to align the interests of the board members with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• Equity compensation for board members, specifically through restricted stock grants, is a standard practice in corporate governance across global markets. Companies like Medtronic (MDT) or Cerner (now Oracle Health) in the healthcare technology sector, for instance, also utilize similar equity-based compensation structures for their directors to incentivize long-term commitment and performance.
• The grant at a $0 price is typical for compensation awards, distinguishing it from open-market purchases and reflecting its nature as a performance or service-based incentive.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of shares to a Director (Bruce E. Scott), which constitutes a related party transaction. However, it is a standard form of compensation for board services and is disclosed as per SEC regulations.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this specific filing, though equity compensation plans are generally part of broader company-wide incentive structures.

Next Steps

• The 6,862 restricted shares granted to Bruce E. Scott are expected to vest in full on June 1, 2026, subject to continued service.

Key Dates

Recommendation

Keywords

Omnicell, OMCL, Form 4, SEC filing, equity compensation, restricted stock, director compensation, insider transaction, corporate governance